Emergent BioSolutions (EBS)
Emergent BioSolutions Profit Margin: -13.57%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
EBS Profit Margin Rankings
| Overall | 13th percentile | 3781 of 4391 |
| Sector | 37th percentile | 294 of 469 in Healthcare |
| Industry | 65th percentile | 45 of 132 in Biotechnology |
EBS Profit Margin Range, Past 5 Years
| Minimum | -115.5% | Mar 2011 |
| Maximum | 30.95% | Dec 2007 |
| Average | 4.36% |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these EBS related companies
EBS News
Emergent BioSolutions (EBS) Receives FDA Approval for BioThrax Treatment
May 17, 5:04PM Street Insider
May 17, 5:04PM Street Insider
Emergent BioSolutions' CEO Hosts Annual Shareholder Meeting Conference (Transcript)
May 17, 1:18PM Seeking Alpha
May 17, 1:18PM Seeking Alpha
Listen to $EBS inc. annual shareholder meeting - live at 09:00 AM, ondemand after - http://stks.co/3rzm
about 12 days ago by earningscast
about 12 days ago by earningscast
Emergent BioSolutions CEOs Discuss 1Q 2012 Results - Earnings Call Transcript
May 04, 12:13AM Seeking Alpha
May 04, 12:13AM Seeking Alpha
Emergent Biosolutions (EBS) Files $180M Mixed Shelf; 3M Common for Shareholders
May 03, 5:15PM Street Insider
May 03, 5:15PM Street Insider
Listen to $EBS Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3f4r
about 25 days ago by earningscast
about 25 days ago by earningscast
$EBS forms bearish "Descending Continuation Triangle" chart pattern. http://stks.co/3cGS
about 27 days ago by RecogniaEvents
about 27 days ago by RecogniaEvents
Leap Wireless International, Jaguar Mining Among Stocks hitting 52-Week Lows Tuesday
May 01, 4:32PM Fox Business
May 01, 4:32PM Fox Business
Emergent BioSolutions Executive Chairman Fuad El-Hibri Named Tech Council of Maryland’s Executive of the Year
Apr 26, 9:30PM Business Wire
Apr 26, 9:30PM Business Wire
Emergent BioSolutions to Release First Quarter 2012 Financial Results and Conduct a Conference Call on May 3, 2012
Apr 12, 7:00AM Business Wire
Apr 12, 7:00AM Business Wire
Emergent BioSolutions Receives NIAID Grant to Support Tuberculosis Vaccine Candidate
Mar 22, 5:06PM Business Wire
Mar 22, 5:06PM Business Wire
Emergent BioSolutions' Management Presents at Lazard Capital Markets Healthcare Conference 2011 (Transcript)
Mar 14, 7:36AM Seeking Alpha
Mar 14, 7:36AM Seeking Alpha
Emergent BioSolutions Management Presents at JPMorgan SMid Cap Conference (Transcript)
Mar 13, 3:12PM Seeking Alpha
Mar 13, 3:12PM Seeking Alpha
Emergent Biosolutions' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Mar 08, 9:41PM Seeking Alpha
Mar 08, 9:41PM Seeking Alpha
Listen to $EBS Q4 2011 earnings call - live at 05:00 PM, ondemand after - http://stks.co/2kIL
about 81 days ago by earningscast
about 81 days ago by earningscast
$EBS Reports Q4 EPS $0.78 vs $0.72 Est; Revenues $107.90M vs $109.32M Est
about 81 days ago by Benzinga
about 81 days ago by Benzinga
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2011
Mar 08, 4:01PM Business Wire
Mar 08, 4:01PM Business Wire
Emergent BioSolutions to Present at Cowen and Company Health Care Conference
Feb 20, 7:00AM Business Wire
Feb 20, 7:00AM Business Wire
I'm lost here, why would Wedbush lower their price tgt today on $EBS to $31 from $37 if they just won a $1.2Billion contract
about 238 days ago by markflowchatter
about 238 days ago by markflowchatter
$EBS
Emergent BioSolutions Reports Q2 EPS $0.39 vs $0.34 Est; Revenues $88.1M vs $84.20M Est
about 298 days ago by Benzinga
about 298 days ago by Benzinga
$EBS - i have been looking at this ahead of earnings. The tape is weak but interesting company and market. Any thoughts??
about 301 days ago by Andiroo33
about 301 days ago by Andiroo33
FDA Gives Fast Track Designation for Emergent BioSolutions' $EBS NuThrax
about 354 days ago by Street_Insider
about 354 days ago by Street_Insider
$EBS $24.02 Harsanyi Zsolt director S 21,600 @ $23.97 amnt $517,646 proc'd ($1,186) 6/6/2011
about 355 days ago by canarionyc
about 355 days ago by canarionyc
$EBS $24.02 Abdun-Nabi Daniel director officer (President & COO) S 178,515 @ $24.58 amnt $4,388,530 proc'd $100,600 6/1/2011
about 361 days ago by canarionyc
about 361 days ago by canarionyc
12:09 $EBS Affirms on track to to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule
about 363 days ago by bricktop13
about 363 days ago by bricktop13
Think like a man of action. Act like a man of thought.
http://imbrogliocapital.blogspot.com/
$TIF, $EBS
about 368 days ago by STG
about 368 days ago by STG
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| EBS | 13.70 | -0.07 | -0.51% | 493.34M |
| EBR | 6.44 | +0.04 | +0.62% | 7.001B |
| EBR.B | 8.71 | +0.28 | +3.32% | 2.312B |
| EBIX | 17.93 | -0.04 | -0.22% | 653.37M |
| EPB | 33.20 | +0.83 | +2.56% | 6.829B |
| EPAY | 18.00 | -0.30 | -1.64% | 652.14M |
| EPAX | 5.12 | -0.01 | -0.19% | 90.06M |
| EP | 28.75 | +0.00 | +0.00% | 22.22B |
| EOS | 10.37 | +0.00 | +0.00% | |
| EONC | 1.11 | +0.00 | +0.00% | 3.186M |